376 related articles for article (PubMed ID: 18408530)
1. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine pharmacology: profile of a dual monoamine modulator.
Karpa KD; Cavanaugh JE; Lakoski JM
CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
[TBL] [Abstract][Full Text] [Related]
4. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
6. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine: a new selective and dual-acting antidepressant.
Bauer M; Möller HJ; Schneider E
Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Westanmo AD; Gayken J; Haight R
Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
[TBL] [Abstract][Full Text] [Related]
10. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Bymaster FP; Lee TC; Knadler MP; Detke MJ; Iyengar S
Curr Pharm Des; 2005; 11(12):1475-93. PubMed ID: 15892657
[TBL] [Abstract][Full Text] [Related]
11. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
12. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
13. [Dual acting reuptake inhibitors in the treatment of depression and pain].
Hajak G
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S280-3. PubMed ID: 17139587
[TBL] [Abstract][Full Text] [Related]
14. Effects of duloxetine on painful physical symptoms associated with depression.
Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA
Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
16. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
17. Duloxetine: a review of its pharmacology and use in chronic pain management.
Bellingham GA; Peng PW
Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
[TBL] [Abstract][Full Text] [Related]
18. Is there a place for duloxetine?
Drug Ther Bull; 2007 Apr; 45(4):29-32. PubMed ID: 17451072
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
